ZYBT vs GDS

For growth investors, GDS Holdings Limited (GDS) is the stronger pick with 7.

7% revenue growth year-over-year, versus -12. 0% for Zhengye Biotechnology Holding Limited (ZYBT). GDS Holdings Limited (GDS) offers the better valuation at 70. 0x trailing P/E (14. 9x forward), making it the more compelling value choice. Analysts rate GDS Holdings Limited (GDS) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, GDS Holdings Limited (GDS) delivered a total return of -41.

4%, compared to -79. 9% for Zhengye Biotechnology Holding Limited (ZYBT). Over 10 years, the gap is even starker: GDS returned +325. 1% versus ZYBT's -79. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Zhengye Biotechnology Holding Limited (ZYBT) is the lower-risk stock at 1.

75β versus GDS Holdings Limited's 2. 13β — meaning GDS is approximately 22% more volatile than ZYBT relative to the S&P 500. On balance sheet safety, Zhengye Biotechnology Holding Limited (ZYBT) carries a lower debt/equity ratio of 25% versus 171% for GDS Holdings Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), GDS Holdings Limited (GDS) is pulling ahead at 7.

7% versus -12. 0% for Zhengye Biotechnology Holding Limited (ZYBT). Over a 3-year CAGR, GDS leads at 6. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

GDS Holdings Limited (GDS) is the more profitable company, earning 8.

3% net margin versus 6. 1% for Zhengye Biotechnology Holding Limited — meaning it keeps 8. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDS leads at 13. 2% versus 8. 8% for ZYBT. At the gross margin level — before operating expenses — ZYBT leads at 49. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ZYBT (5.

3% yield) pays a dividend. GDS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Zhengye Biotechnology Holding Limited (ZYBT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (5.

3% yield). GDS Holdings Limited (GDS) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ZYBT: -79. 9%, GDS: +325. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ZYBT (Healthcare) and GDS (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ZYBT is a small-cap income-oriented stock; GDS is a small-cap quality compounder stock. ZYBT pays a dividend while GDS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.